Literature DB >> 35932436

Validation of catalytic site residues of Ubiquitin Specific Protease 2 (USP2) by molecular dynamic simulation and novel kinetics assay for rational drug design.

Shafi Ullah1, Muhammad Junaid2, Yunqi Liu3, Shiyao Chen3, Yaxue Zhao3, Abdul Wadood4.   

Abstract

Post-translational modifications of proteins such as protein ubiquitination are crucial for regulating conformation, stability and localization of the modified protein. Ubiquitin-specific protease 2 (USP2), a multifunctional cysteine protease is reported to be a key regulator of ubiquitylation events in numerous oncogenic proteins e.g., fatty acid synthetase, Mdm2, EGFR, cyclin A1, and cyclin-D1, etc. Thus targeting USP2 is a promising strategy for cancer therapy. USP2 is characterized by a catalytic triad comprising of cysteine, histidine and aspartic acid residues. Five residues including three from the catalytic triad and two from outside of the catalytic triad have been reported as a catalytic site of USP2 that catalyze hydrolysis and stabilizes the oxyanion formed in the intermediate step of catalysis. Here, we report two more novel residues (L269 and Y558) on USP2 involved in the catalysis of Ubiquitin using computational alanine scanning (CAS) followed by molecular dynamic simulation studies. The results obtained from CAS were further validated by a highly reliable, time- and cost-effective SDS-PAGE-based kinetics assay using UBA52 which is a natural substrate of USP2. Our results showed that mutating L269 and Y558 significantly compromised the catalytic efficiency of USP2 in hydrolyzing UBA52 which can further be extended to rational drug design of USP2 selective inhibitors and to explore the catalytic sites of other USPs. Two novel residues take part in catalytic activity of USP2 which were depicted by MD Simulations and were further validated by novel SDS-PAGE-based reliable time- and cost-effective kinetics assay.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Catalytic site; Kinetics assay; Proteasome; Rational drug design; USP2

Year:  2022        PMID: 35932436     DOI: 10.1007/s11030-022-10499-1

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   3.364


  24 in total

Review 1.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

2.  Basic Medical Research Award. The ubiquitin system.

Authors:  A Hershko; A Ciechanover; A Varshavsky
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

Review 3.  Modification of proteins by ubiquitin and ubiquitin-like proteins.

Authors:  Oliver Kerscher; Rachael Felberbaum; Mark Hochstrasser
Journal:  Annu Rev Cell Dev Biol       Date:  2006       Impact factor: 13.827

Review 4.  Breaking the chains: structure and function of the deubiquitinases.

Authors:  David Komander; Michael J Clague; Sylvie Urbé
Journal:  Nat Rev Mol Cell Biol       Date:  2009-08       Impact factor: 94.444

5.  Contribution of active site residues to substrate hydrolysis by USP2: insights into catalysis by ubiquitin specific proteases.

Authors:  Wanfang Zhang; Traian Sulea; Limei Tao; Qizhi Cui; Enrico O Purisima; Ratsavarinh Vongsamphanh; Paule Lachance; Viktoria Lytvyn; Hongtao Qi; Yuxin Li; Robert Ménard
Journal:  Biochemistry       Date:  2011-05-04       Impact factor: 3.162

6.  Quantitative analysis of global ubiquitination in HeLa cells by mass spectrometry.

Authors:  David Meierhofer; Xiaorong Wang; Lan Huang; Peter Kaiser
Journal:  J Proteome Res       Date:  2008-09-10       Impact factor: 4.466

7.  Divergence in Ubiquitin Interaction and Catalysis among the Ubiquitin-Specific Protease Family Deubiquitinating Enzymes.

Authors:  Adam H Tencer; Qin Liang; Zhihao Zhuang
Journal:  Biochemistry       Date:  2016-08-08       Impact factor: 3.162

Review 8.  Targeting the ubiquitin system in cancer therapy.

Authors:  Daniela Hoeller; Ivan Dikic
Journal:  Nature       Date:  2009-03-26       Impact factor: 49.962

Review 9.  Deubiquitylating enzymes and drug discovery: emerging opportunities.

Authors:  Jeanine A Harrigan; Xavier Jacq; Niall M Martin; Stephen P Jackson
Journal:  Nat Rev Drug Discov       Date:  2017-09-29       Impact factor: 84.694

10.  Structural basis of ubiquitin recognition by the deubiquitinating protease USP2.

Authors:  Martin Renatus; Shirley Gil Parrado; Allan D'Arcy; Ulf Eidhoff; Bernd Gerhartz; Ulrich Hassiepen; Benoit Pierrat; Ralph Riedl; Daniela Vinzenz; Susanne Worpenberg; Markus Kroemer
Journal:  Structure       Date:  2006-08       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.